Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Status:
Completed
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, antitumor activity and preliminary pharmacokinetics of
an investigational drug product, DTRMWXHS-12, in patients with chronic lymphocytic leukemia
or other B-cell lymphomas. DTRMWXHS-12 will be evaluated as a single agent, and in
combination.
This study will be conducted in two parts: phase Ia and Ib. Both parts will explore
escalating doses of DTRMWXHS-12. The phase Ia study will evaluate DTRMWXHS-12 monotherapy.
The phase Ib study will evaluate DTRMWXHS-12 combinations.